GLP-1s appear to be more than weight loss drugs, potentially offering direct joint protection and dramatically reducing surgical risk. By the numbers  Recent research demonstrates significant clinical benefits across multiple measures: 40% of obese patients with known hip arthritis prescribed a GLP-1 showed a reduced risk of hip replacement within one year, based on data from 239,000+ patients. 25% of obese patients with known knee arthritis on a GLP-1 demonstrated a reduce